Pohlen et al developed a model for predicting mortality for a patient with acute myeloid leukemia (AML) who has been discharged from the ICU. This can help to identify a patient who may benefit from admission to the ICU. The authors are from University Hospital Muenster in Germany.
Patient selection: AML admitted to ICU
Outcome: mortality after discharge from ICU
Parameters:
(1) AML disease status
(2) allogeneic stem cell transplant
(3) days in the hospital before the ICU admission
(4) days spent in the ICU
(5) urine production at ICU admission
(6) Glasgow coma score at ICU admission
(7) hematocrit at ICU admission
|
Parameter |
Finding |
Points |
|
AML disease status |
newly diagnosed |
0 |
|
|
in remission |
0 |
|
|
refractory (advanced) |
1.886 |
|
|
relapsed (advanced) |
1.886 |
|
allogeneic stem cell transplant |
no |
0 |
|
|
yes |
0.974 |
|
days in the hospital before |
|
<days> * 0.036 |
|
days in the ICU |
|
<days> * (-0.055) |
|
urine output at ICU admission |
>= 1,000 mL per 24 hours |
0 |
|
|
< 1,000 mL per 24 hours |
1.789 |
|
Glasgow coma score |
>= 8 |
0 |
|
|
< 8 |
1.465 |
|
hematocrit |
>= 25% |
0 |
|
|
< 25% |
(-1.51) |
total score =
= SUM(points for all 7 parameters)
|
Total Score |
Risk Group |
1-Year Survival |
|
< 0.23 |
low |
100% |
|
0.23 to 2.33 |
intermediate |
82% |
|
> 2.33 |
high |
42% |
Specialty: Critical Care, Emergency Medicine, Hematology Oncology, Surgery, general
